India Nicotine Replacement Therapy Market Overview,2030

The nicotine replacement therapy (NRT) market in India is shaped by the country’s exceptionally large tobacco-using population, widespread use of both smoking and smokeless tobacco, and evolving public health policies. India is home to over 260 million tobacco users, with about 100 million smokers and more than 180 million smokeless tobacco consumers, making it the second-largest tobacco market globally after China. NRT was first introduced in India in the early 2000s, primarily through multinational players like Johnson & Johnson (Nicorette) offering gums and lozenges. Early adoption was slow due to low awareness, high costs, and limited focus on cessation in India’s public health framework, which historically prioritized prevention and disease management over quitting support. A turning point came with the launch of the National Tobacco Control Programme (NTCP) in 2007, which incorporated smoking cessation as a key priority. Government-run Tobacco Cessation Clinics began promoting NRT as part of structured quitting programs, though coverage remained urban-centric. Over the past decade, India’s rising burden of non-communicable diseases, linked strongly to tobacco use, has driven greater emphasis on cessation support. As of 2024, India’s NRT market is valued at approximately USD 50–70 million, far below its potential relative to the population size. The market is dominated by gums, with patches and lozenges available in urban pharmacies and select hospital programs. Despite its small base, the market is gradually expanding, supported by rising health awareness, urbanization, and growing integration of NRT into government-led cessation campaigns. However, high tobacco affordability and cultural acceptance continue to limit large-scale adoption.

According to the research report ""India Nicotine Replacement Therapy Market Overview, 2030,"" published by Bonafide Research, the India Nicotine Replacement Therapy market is anticipated to grow at 16.15% CAGR from 2025 to 2030. India presents one of the world’s largest untapped opportunities for NRT adoption, given its vast tobacco-using population and increasing government commitment to tobacco control. Regulatory oversight comes under the Central Drugs Standard Control Organisation (CDSCO), which approves NRT products as pharmaceuticals. Unlike some developed nations, India does not yet provide reimbursement for NRT through public health insurance schemes such as Ayushman Bharat, meaning most purchases are out-of-pocket. However, opportunities lie in integrating NRT into the NTCP more comprehensively, ensuring subsidies for low-income users, and expanding distribution beyond urban centers. Current trends show rising demand for NRT gums and lozenges, which are preferred due to affordability and discreet use. Innovative delivery methods, such as fast-dissolving strips and sprays, remain limited but represent growth areas. Digital health is emerging as an important support system, with mobile apps and telemedicine platforms increasingly offering cessation counseling bundled with NRT recommendations. Strategic recommendations include introducing low-cost generic NRT to improve affordability, leveraging India’s extensive primary healthcare network to promote adoption in rural areas, and linking NRT with large-scale public awareness campaigns. Another important strategy is employer-driven wellness programs, particularly in the IT and corporate sectors, where cessation support can be integrated into workplace health benefits. A key challenge is competition from smokeless tobacco products, which are cheap, culturally entrenched, and not easily addressed through traditional NRT formats. Long-term opportunities lie in expanding the product mix, securing policy-level support for subsidies, and positioning NRT as an essential tool in India’s goal of reducing tobacco use prevalence under WHO FCTC commitments.

India’s nicotine alternatives market is dominated by NRT and smokeless tobacco substitutes, with minimal presence of e-cigarettes or heated tobacco products due to regulatory bans. NRT is the only medically validated cessation aid legally available, with gums leading the category. Nicorette gums, available in 2mg and 4mg strengths, hold the largest market share, supplemented by lozenges and limited availability of patches in urban hospitals and pharmacies. Domestic generic players have begun to introduce lower-cost gums to expand access, but penetration remains low. Unlike Western markets, India banned e-cigarettes in 2019 under the Prohibition of Electronic Cigarettes Act, which outlawed production, import, and sale of vaping products nationwide. This has effectively eliminated vaping as a competitor to NRT. Similarly, heated tobacco products like IQOS and glo are not legally sold in India, though small volumes enter through illicit channels. As a result, the competitive landscape for NRT is shaped less by alternative nicotine technologies and more by deeply entrenched smokeless tobacco consumption, such as gutka, khaini, and betel quid, which are inexpensive and socially integrated. This dynamic creates unique challenges for NRT, as products like gums and lozenges must not only substitute for smoking but also address cravings from smokeless tobacco use. Research and pilot programs in India suggest modified NRT protocols, including higher-dose therapies, are effective for smokeless users, representing a niche growth opportunity. Total, India’s product segmentation gives NRT an exclusive position as the only regulated cessation aid, but uptake will depend on pricing, awareness, and expansion of product formats suited to Indian consumers.

In India, the NRT market is overwhelmingly dominated by over-the-counter (OTC) sales. Nicotine gums and lozenges are widely available in retail pharmacies, supermarkets, and online platforms without a prescription, appealing to smokers seeking quick, self-directed cessation solutions. OTC access ensures reach across urban centers, though penetration in rural areas remains limited. Prescription-based sales are minimal, largely confined to government Tobacco Cessation Clinics and private hospitals that incorporate NRT into structured cessation programs. These clinics, supported under the NTCP, provide NRT as part of counseling-based interventions but operate in relatively small numbers compared to the overall tobacco-using population. The lack of insurance reimbursement and limited awareness among physicians have also hindered prescription-driven adoption. Most doctors in India recommend NRT informally, encouraging patients to purchase gums or lozenges OTC rather than through formal prescription channels. Strategic growth opportunities include strengthening physician-led prescription programs, integrating NRT into public health insurance schemes, and expanding clinical cessation services to cover rural and semi-urban areas. In the current market, however, OTC sales account for more than 85% of NRT revenue, sustained by consumer-driven demand and strong pharmacy networks in urban areas. While prescription-based sales remain underdeveloped, they represent an important long-term opportunity, particularly if NRT is embedded into chronic disease management programs for cardiovascular health, diabetes, and respiratory conditions. A dual-structured approach, balancing OTC accessibility with clinical prescription programs, will be key to scaling adoption in India’s vast and diverse market.

Distribution of NRT in India is led by offline channels, with retail pharmacies accounting for the majority of sales. India has more than 800,000 pharmacies nationwide, which serve as the backbone of healthcare distribution, particularly in urban and semi-urban areas. Supermarkets and convenience stores also sell NRT gums, enhancing accessibility for consumers seeking quick purchases. Hospitals and government Tobacco Cessation Clinics contribute to prescription-based distribution but represent a small share of total sales. Offline channels benefit from trust, physical presence, and ease of access, making them the dominant distribution model. Online channels, however, are growing rapidly, driven by India’s booming e-commerce and digital health ecosystem. Platforms such as PharmEasy, 1mg (now Tata 1mg), and NetMeds offer NRT products with home delivery, price discounts, and bundled health consultations, appealing to younger and digitally savvy consumers. The COVID-19 pandemic accelerated this shift, as many consumers turned to online pharmacies for essential healthcare needs. Online channels also play an important role in discreet purchases, which is valuable in India, where social stigma around tobacco use persists in certain segments. Despite their rapid growth, online sales account for less than 20% of the market, as offline pharmacies remain the default point of access. Going forward, hybrid models combining offline pharmacy networks with digital platforms will shape India’s distribution landscape. With the rapid expansion of internet penetration and digital health adoption, online channels are expected to grow at double-digit rates, gradually reshaping how NRT is purchased and integrated into broader cessation support systems.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Nicotine Replacement Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Nicotine Replacement Therapy
• E-cigarettes
• Heat-not-burn tobacco products
By Nicotine Replacement Therapy
• Nicotine Gums
• Nicotine Lozenges
• Nicotine Nasal Sprays
• Nicotine Pouches
• Others (Nicotine Patches, Nicotine Inhalers & Others)
By Sales Type
• Over-the-Counter (OTC)
• Prescription-Based

By Distribution Channel
• Offline
• Online
Show more